Abstract 1207P
Background
Neurotrophin tyrosine receptor kinase (NTRK) arrangement (NTRK+) are rare but actionable oncogenic drivers present in a wide variety of solid tumors. More than 20 different fusion partner genes of NTRK have been reported and most of these NTRK fusions respond well to NTRK inhibitors larotrectinib and/or entrectinib. With the development of next-generation sequencing (NGS), more novel partners for NTRK rearrangement have been identified. Here, we aimed to report the landscape of NTRK rearrangement in Chinese patients with solid tumors.
Methods
Tissue specimens and/or circulating cell-free DNA from patients were subjected to NGS in a College of American Pathologists-certified and Clinical Laboratory Improvement Amendments-accredited lab for NTRK arrangement.
Results
In total, we profiled more than 40,000 patients, among which 17 cases with 11 NTRK fusion partner, harboring 4 reported partners (CD74, ETV6, IRF2BP2, and LMNA) and 7 novel partners (AGBL1, ASH1L, CGN, DCAF12, DDX10, DMD, LIPI). The average NTRK rearrangement patients' age was 53 years (range, 4-89 years). Among all the NTRK fusion cases (n=17), lung cancer were the largest proportion with 52.9% (n=9), colorectal cancer, liver cancer, thyrophyma, soft tissue tumor, neuroendocrine cancer, schwannoma, gastrointestinal stromal tumor, esophageal squamous cell carcinoma biliary cancer, accounted for 5.9% (n=1) respectively. The most common reported NTRK fusion partners were ETV6 (n=3) and LMNA (n=5). In 9 cases, 6 novel NTRK fusion partners were discovered. The novel LIPI-NTRK1 occurred three times in 3 lung cancer patients. There was a special schwannoma cases with LMNA-NTRK1 fusions, who was a 4-year-old boy.
Conclusions
Novel NTRK fusions are detected in patients with not only lung cancer but also other solid tumors. NGS fusion assay is an optional method for screening novel fusions.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.